Joana Caiado1,2, Mariana C Castells3. 1. Immunoallergology Department, Hospital Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Av. Professor Egas Moniz, 1649-035, Lisbon, Portugal. joanacaiado@hotmail.com. 2. Faculdade de Medicina de Lisboa, Universidade de Lisboa, Lisbon, Portugal. joanacaiado@hotmail.com. 3. Division of Allergy and Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Abstract
Hypersensitivity reactions (HSRs) to antineoplastic drugs are increasing due to the expanding use of classical and new drugs in a wide variety of malignancies. PURPOSE OF REVIEW: The goal of this review is to provide current best practices in the diagnosis and management of HSRs based on data and evidence. RECENT FINDINGS: A plethora of studies have provided evidence of the safety and efficacy of rapid drug desensitizations (RDD) to allow for the reintroduction of antineoplastic drugs following an HSR, based on risk stratification. Recently described biomarkers such as basophil activation test, total IgE, BRCA genotyping, and serum IL-6 can aid in guiding improved precision desensitization protocols. Personalized premedication regimens and protocols have improved RDD safety and outcomes. RDD allows for the continued use of chemotherapeutic drugs without impaired drug efficacy. RDD represents the best approach to maintain cancer patients on their most effective treatments.
Hypersensitivity reactions (HSRs) to antineoplastic drugs are increasing due to the expanding use of classical and new drugs in a wide variety of malignancies. PURPOSE OF REVIEW: The goal of this review is to provide current best practices in the diagnosis and management of HSRs based on data and evidence. RECENT FINDINGS: A plethora of studies have provided evidence of the safety and efficacy of rapid drug desensitizations (RDD) to allow for the reintroduction of antineoplastic drugs following an HSR, based on risk stratification. Recently described biomarkers such as basophil activation test, total IgE, BRCA genotyping, and serum IL-6 can aid in guiding improved precision desensitization protocols. Personalized premedication regimens and protocols have improved RDD safety and outcomes. RDD allows for the continued use of chemotherapeutic drugs without impaired drug efficacy. RDD represents the best approach to maintain cancerpatients on their most effective treatments.
Authors: David Sloane; Usha Govindarajulu; Jacob Harrow-Mortelliti; William Barry; Florence Ida Hsu; David Hong; Tanya Laidlaw; Ross Palis; Henry Legere; Supinda Bunyavanich; Rebecca Breslow; Duane Wesemann; Nora Barrett; Patrick Brennan; Hey Jin Chong; Anne Liu; James Fernandez; Laura Fanning; Timothy Kyin; Katherine Cahill; Lora Bankova; Ashly Lynch; Suzanne Berlin; Susana Campos; Charles Fuchs; Robert Mayer; Ursula Matulonis; Mariana Castells Journal: J Allergy Clin Immunol Pract Date: 2016-02-16
Authors: Mariana C Castells; Nichole M Tennant; David E Sloane; F Ida Hsu; Nora A Barrett; David I Hong; Tanya M Laidlaw; Henry J Legere; Samridhi N Nallamshetty; Ross I Palis; Jayanti J Rao; Suzanne T Berlin; Susana M Campos; Ursula A Matulonis Journal: J Allergy Clin Immunol Date: 2008-05-27 Impact factor: 10.793
Authors: Patrick J Brennan; Tito Rodriguez Bouza; F Ida Hsu; David E Sloane; Mariana C Castells Journal: J Allergy Clin Immunol Date: 2009-12 Impact factor: 10.793
Authors: R Madrigal-Burgaleta; M P Berges-Gimeno; D Angel-Pereira; R Ferreiro-Monteagudo; C Guillen-Ponce; C Pueyo; E Gomez de Salazar; E Alvarez-Cuesta Journal: Allergy Date: 2013-05-06 Impact factor: 13.146
Authors: Jitesh Chauhan; Chara Stavraka; Melanie Grandits; Lais C G F Palhares; Debra H Josephs; Katie E Lacy; James Spicer; Heather J Bax; Sophia N Karagiannis Journal: Cells Date: 2022-01-27 Impact factor: 7.666